The Market Lifts Cabio Biotech (Wuhan) Co., Ltd. (SHSE:688089) Shares 27% But It Can Do More

Cabio Biotech (Wuhan) Co., Ltd. (SHSE:688089) shareholders are no doubt pleased to see that the share price has bounced 27% in the last month, although it is still struggling to make up recently lost ground. Not all shareholders will be feeling jubilant, since the share price is still down a very disappointing 48% in the last twelve months.

Although its price has surged higher, Cabio Biotech (Wuhan) may still be sending bullish signals at the moment with its price-to-earnings (or "P/E") ratio of 28.2x, since almost half of all companies in China have P/E ratios greater than 33x and even P/E's higher than 60x are not unusual. However, the P/E might be low for a reason and it requires further investigation to determine if it's justified.

Recent times have been advantageous for Cabio Biotech (Wuhan) as its earnings have been rising faster than most other companies. It might be that many expect the strong earnings performance to degrade substantially, which has repressed the P/E. If you like the company, you'd be hoping this isn't the case so that you could potentially pick up some stock while it's out of favour.

Check out our latest analysis for Cabio Biotech (Wuhan)

Want the full picture on analyst estimates for the company? Then our free report on Cabio Biotech (Wuhan) will help you uncover what's on the horizon.

Is There Any Growth For Cabio Biotech (Wuhan)?

In order to justify its P/E ratio, Cabio Biotech (Wuhan) would need to produce sluggish growth that's trailing the market.

If we review the last year of earnings growth, the company posted a terrific increase of 40%. Despite this strong recent growth, it's still struggling to catch up as its three-year EPS frustratingly shrank by 30% overall. So unfortunately, we have to acknowledge that the company has not done a great job of growing earnings over that time.

Turning to the outlook, the next year should generate growth of 52% as estimated by the two analysts watching the company. That's shaping up to be materially higher than the 40% growth forecast for the broader market.

With this information, we find it odd that Cabio Biotech (Wuhan) is trading at a P/E lower than the market. It looks like most investors are not convinced at all that the company can achieve future growth expectations.

The Key Takeaway

Despite Cabio Biotech (Wuhan)'s shares building up a head of steam, its P/E still lags most other companies. We'd say the price-to-earnings ratio's power isn't primarily as a valuation instrument but rather to gauge current investor sentiment and future expectations.

We've established that Cabio Biotech (Wuhan) currently trades on a much lower than expected P/E since its forecast growth is higher than the wider market. When we see a strong earnings outlook with faster-than-market growth, we assume potential risks are what might be placing significant pressure on the P/E ratio. At least price risks look to be very low, but investors seem to think future earnings could see a lot of volatility.

You always need to take note of risks, for example - Cabio Biotech (Wuhan) has 1 warning sign we think you should be aware of.

Of course, you might also be able to find a better stock than Cabio Biotech (Wuhan). So you may wish to see this free collection of other companies that have reasonable P/E ratios and have grown earnings strongly.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.